ACRS - Aclaris Therapeutics Inc. (ACRS) Q1 2024 Earnings Call Transcript
2024-05-07 21:44:02 ET
Aclaris Therapeutics, Inc. (ACRS)
Q1 2024 Results Conference Call
May 07, 2024 5:00 PM ET
Company Participants
Kevin Balthaser - Chief Financial Officer
Neal Walker - Interim Chief Executive Officer
Joe Monahan - Chief Scientific Officer
Wally Smith - Scientific & Business Development Consultant
Conference Call Participants
Roger Song - Jefferies
Thomas Smith - Leerink Partners
Corinne Jenkins - Goldman Sachs
Julian Harrison - Big TIG
Alex Thompson - Stifel
Gavin Clark-Gartner - Evercore ISI
Presentation
Operator
Good day, and thank you for standing by. Welcome to the Aclaris Therapeutics First Quarter 2024 Conference Call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised that today's conference is being recorded.
I would now like to hand the conference over to your speaker today, Kevin Balthaser. Please go ahead.
Kevin Balthaser
Thank you. I am Kevin Balthaser, Chief Financial Officer for Aclaris. Please note that earlier today, we issued a press release highlighting our first quarter 2024 financial results and other business matters. For those of you who have not yet seen it, you will find the release posted under the Press Releases page of the Investors section of our website at www.aclaristx.com. In addition, we will be referring to a slide deck entitled ITK Portfolio, which can be found on the Investor Presentations page of the Investors section of our website and furnished as an exhibit to our Form 8-K that we filed with the SEC earlier today....
Aclaris Therapeutics, Inc. (ACRS) Q1 2024 Earnings Call Transcript